366 related articles for article (PubMed ID: 27712634)
1. Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome.
Muchtar E; Derudas D; Mauermann M; Liewluck T; Dispenzieri A; Kumar SK; Dingli D; Lacy MQ; Buadi FK; Hayman SR; Kapoor P; Leung N; Chakraborty R; Gonsalves W; Russell S; Lust JA; Lin Y; Go RS; Zeldenrust S; Kyle RA; Rajkumar SV; Gertz MA
Mayo Clin Proc; 2016 Oct; 91(10):1354-1361. PubMed ID: 27712634
[TBL] [Abstract][Full Text] [Related]
2. Characterization of isolated amyloid myopathy.
Liewluck T; Milone M
Eur J Neurol; 2017 Dec; 24(12):1437-1445. PubMed ID: 28888072
[TBL] [Abstract][Full Text] [Related]
3. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
4. Muscle involvement with pseudohypertrophy in systemic light chain amyloidosis: Case report.
Draghici M; Jercan A; Badelita SN; Irimia RM; Bastian AE; Dobrea C; Popescu M; Coriu D
Medicine (Baltimore); 2021 Dec; 100(51):e28267. PubMed ID: 34941106
[TBL] [Abstract][Full Text] [Related]
5. Case report: One case of primary AL amyloidosis repeatedly misdiagnosed as scleroderma.
Sun L; Zhang L; Hu W; Li TF; Liu S
Medicine (Baltimore); 2017 Dec; 96(50):e8771. PubMed ID: 29390268
[TBL] [Abstract][Full Text] [Related]
6. Myopathy in primary systemic amyloidosis.
Gertz MA; Kyle RA
J Neurol Neurosurg Psychiatry; 1996 Jun; 60(6):655-60. PubMed ID: 8648333
[TBL] [Abstract][Full Text] [Related]
7. Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.
Mahmood S; Bridoux F; Venner CP; Sachchithanantham S; Gilbertson JA; Rowczenio D; Wagner T; Sayed R; Patel K; Fontana M; Whelan CJ; Lachmann HJ; Hawkins PN; Gillmore JD; Wechalekar AD
Lancet Haematol; 2015 Jun; 2(6):e241-50. PubMed ID: 26688234
[TBL] [Abstract][Full Text] [Related]
8. Systemic light-chain amyloidosis presenting with rapid progressive heart failure.
Sunbul M; Durmus E; Kivrak T; Besiroglu F; Gerin F; Sari I; Mutlu B
Ther Adv Cardiovasc Dis; 2013 Aug; 7(4):224-7. PubMed ID: 23868674
[TBL] [Abstract][Full Text] [Related]
9. Chronic myopathy due to immunoglobulin light chain amyloidosis.
Manoli I; Kwan JY; Wang Q; Rushing EJ; Tsokos M; Arai AE; Burch WM; Dispenzieri A; McPherron AC; Gahl WA
Mol Genet Metab; 2013 Apr; 108(4):249-54. PubMed ID: 23465863
[TBL] [Abstract][Full Text] [Related]
10. Amyloid myopathy presenting with distal atrophic weakness.
Smestad C; Monstad P; Lindboe CF; Mygland A
Muscle Nerve; 2004 Apr; 29(4):605-9. PubMed ID: 15052628
[TBL] [Abstract][Full Text] [Related]
11. Dysarthria and dysphagia from light chain amyloidosis.
Tabbarah K; Madden J; Bedlack RS
Neurology; 2005 Nov; 65(10):1671. PubMed ID: 16301506
[No Abstract] [Full Text] [Related]
12. Monoclonal gammopathy of renal significance (MGRS)-related AL amyloidosis complicated by amyloid myopathy: a case report.
Ono E; Ishii A; Higashi Y; Koita N; Ayaki T; Tanigaki K; Takayanagi S; Kondo N; Sakai K; Endo S; Yokoi H; Matsubara T; Minamiguchi S; Nishino I; Takahashi R; Yanagita M
BMC Nephrol; 2021 Feb; 22(1):74. PubMed ID: 33639890
[TBL] [Abstract][Full Text] [Related]
13. The diagnosis and characteristics of renal heavy-chain and heavy/light-chain amyloidosis and their comparison with renal light-chain amyloidosis.
Nasr SH; Said SM; Valeri AM; Sethi S; Fidler ME; Cornell LD; Gertz MA; Dispenzieri A; Buadi FK; Vrana JA; Theis JD; Dogan A; Leung N
Kidney Int; 2013 Mar; 83(3):463-70. PubMed ID: 23302715
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2018 Sep; 93(9):1169-1180. PubMed ID: 30040145
[TBL] [Abstract][Full Text] [Related]
15. Teaching neuroimages: dyspnea as a presenting manifestation of amyloid myopathy.
Ghosh PS; Thaera GM; Tracy JA
Neurology; 2013 Dec; 81(24):e184. PubMed ID: 24323446
[TBL] [Abstract][Full Text] [Related]
16. Expanding the spectrum of monoclonal light chain deposition disease in muscle.
Ostrow LW; Corse AM; Morrison BM; Huff CA; Carrino JA; Hoke A; Mammen AL
Muscle Nerve; 2012 May; 45(5):755-61. PubMed ID: 22499107
[TBL] [Abstract][Full Text] [Related]
17. [Myopathy and mixed hyperlipoproteinemia as the first symptom of systemic AL-amyloidosis].
Tosovský M; Soukup T; Bradna P; Maisnar V; Tycová V; Toms J; Prixová M
Vnitr Lek; 2008 Oct; 54(10):1014-9. PubMed ID: 19009771
[TBL] [Abstract][Full Text] [Related]
18. [Giant tongue leading to dysphagia in light chain amyloidosis patient].
Gómez-Piña JJ; Quiroz DM; Sierra-Hernández A; Mendoza-Álvarez SA; Vera-Lastra OL
Rev Med Inst Mex Seguro Soc; 2023 Nov; 61(6):863-867. PubMed ID: 37995383
[TBL] [Abstract][Full Text] [Related]
19. [A case of amyloid myopathy diagnosed during the treatment of myopathy associated with anti-signal recognition particle antibodies].
Kawakami N; Katsuyama Y; Hagiwara Y; Yoshida H; Kim K; Harada K
Rinsho Shinkeigaku; 2017 Apr; 57(4):168-173. PubMed ID: 28367947
[TBL] [Abstract][Full Text] [Related]
20. Immunoglobulin light and heavy chain amyloidosis AL/AH: renal pathology and differential diagnosis.
Picken MM
Contrib Nephrol; 2007; 153():135-55. PubMed ID: 17075228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
